2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10943
    APO-15 3051946-11-0 99.45%
    APO-15 is a phosphatidylserine-binding fluorescent probe and apoptosis imaging reagent. APO-15 exhibits high chemical stability under proteolytic and oxidative conditions, enables quantification and imaging of drug-induced apoptosis in preclinical mouse models, and is applicable to fixed tissue samples and multiple in vivo administration routes (Ex = 488 nm; Em = 525 nm). APO-15 can be used in studies related to acute lung injury and breast cancer.
    APO-15
  • HY-P11077
    LR-17 1256099-50-9
    LR-17 (TLT-1 (94-110)), a 17-aa peptide, is a TREM-1 inhibitor. LR-17 shows anti-inflammatory effects that can reduce the secretion of pro-inflammatory cytokines induced by Lipopolysaccharides (HY-D1056) (LPS). LR-17 can be used for the study of sepsis.
    LR-17
  • HY-P11107
    RP-832c 2375823-45-1 99.86%
    RP-832c is a synthetic analogue of host defense peptides (HDP), targeting the mannose receptor CD206 on the surface of M2 polarized macrophages (Kd = 3.5 μM). RP-832c binding to CD206 induces a significant conformational change in the receptor, activating signaling pathways that lead to rapid apoptosis and repolarization of CD206-positive M2 macrophages to an M1 phenotype. RP-832c treatment significantly reduces CD206 gene expression in M2 macrophages while transiently increasing expression of TNF-α, a marker for M1 macrophages. RP-832c is used for the studies of T-cell lymphoma (CTCL) and idiopathic pulmonary fibrosis (IPF).
    RP-832c
  • HY-P11108
    RP-182 1895883-60-9 98.68%
    RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research.
    RP-182
  • HY-P11306
    Biotin-(Oaa)3-epoxomicin 247068-92-4
    Biotin-(Oaa)3-epoxomicin is a biotin-labeled form of Epoxomicin (HY-13821), prepared by conjugating Epoxomicin with biotin via three hydrophilic oxaacetyl amino acid (Oaa) linkers. Biotin-(Oaa)3-epoxomicin is primarily used in proteomic studies for the capture, identification and target validation of proteasome complexes, to determine the intracellular targets of epoxomicin. Epoxomicin acts as a proteasome inhibitor and NF-κB inhibitor, which effectively blocks inflammatory responses in mouse ear edema assays. It inhibits proteasome activity via covalent binding to catalytic subunits including LMP7, X, MECL1 and Z, with the strongest inhibitory effect on chymotrypsin-like activity, and does not interfere with non-proteasomal proteases such as trypsin and papain.
    Biotin-(Oaa)3-epoxomicin
  • HY-P1346A
    APETx2 TFA 99.57%
    APETx2 TFA, a sea anemone peptide from Anthopleura elegantissima, is a selective and reversible ASIC3 inhibitor, with an IC50 of 63 nM. APETx2 directly inhibits the ASIC3 channel by acting at its external side. APETx2 could reverses acid‐induced and inflammatory pain.
    APETx2 TFA
  • HY-P1377A
    Caffeic acid-pYEEIE TFA 98.47%
    Caffeic acid-pYEEIE TFA, a phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.
    Caffeic acid-pYEEIE TFA
  • HY-P1645A
    Papain (1.5-10 units/mg) 9001-73-4
    Papain (1.5-10 units/mg) is a cysteine protease of the peptidase C1 family. Papain (1.5-10 units/mg) enhances red cell agglutination by anti-D and anti-A, and increases red cell sensitivity to K cell-mediated lysis in ADCC assays. Papain (1.5-10 units/mg) can induce pulmonary emphysema. Papain (1.5-10 units/mg) can be used for the researches of Rh haemolytic disease of the newborn and pulmonary emphysema.
    Papain (1.5-10 units/mg)
  • HY-P2294A
    pm26TGF-β1 peptide TFA 99.68%
    pm26TGF-β1 TFA peptide is a peptide that mimics a portion of the human TGF-β1 molecule. pm26TGF-β1 peptide TFA shows high affinity for the TGF-β1 receptor. pm26TGF-β1 peptide TFA displays potent anti-inflammatory properties and does not exhibit neutrophils’ chemoattraction.
    pm26TGF-β1 peptide TFA
  • HY-P2818A
    Alkaline phosphatase, Escherichia coli 9001-78-9
    Alkaline Phosphatase (Apase), Escherichia coli is an alkaline phosphatase from Escherichia coli, and is one of the most active alkaline phosphatases. Alkaline phosphatase, Escherichia coli is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase, Escherichia coli reduces myeloperoxidase activity and bacterial translocation. Alkaline phosphatase, Escherichia coli improves survival rate of mice infected with E. coli. Alkaline phosphatase, Escherichia coli improves TNBS-induced colon inflammation.
    Alkaline phosphatase, Escherichia coli
  • HY-P2818C
    Alkaline phosphatase, microorganism 9001-78-9
    Alkaline Phosphatase (Apase), microorganism is an alkaline phosphatase from microorganism, and is one of the most active alkaline phosphatases. Alkaline phosphatase, microorganism is an orally active membrane-bound glycoprotein that catalyzes the hydrolysis of phosphate monoesters at alkaline pH. Alkaline phosphatase, microorganism reduces myeloperoxidase activity and bacterial translocation. Alkaline phosphatase, microorganism improves survival rate of mice infected with E. coli. Alkaline phosphatase, microorganism improves TNBS-induced colon inflammation.
    Alkaline phosphatase, microorganism
  • HY-P3494B
    Hepcidin-25 (human) TFA
    Hepcidin-25 (human) TFA is an iron metabolism modulator and Antimicrobial agent. Hepcidin-25 (human) TFA shows anti-inflammatory and anti-bacterial activity via modulation of iron-mediated oxidant injury.
    Hepcidin-25 (human) TFA
  • HY-P5502A
    Influenza NP (311-325) TFA
    Influenza NP (311-325) TFA is an Influenza A nucleoprotein peptide. Influenza NP (311-325) TFA is a class II restricted epitope. Influenza NP (311-325) Influenza NP (311-325) TFA fused to OVA protein can be used for immunological response studies.
    Influenza NP (311-325) TFA
  • HY-P99298
    Lampalizumab 1278466-20-8 99.46%
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.
    Lampalizumab
  • HY-P99572
    Tecaginlimab 2253891-70-0 99.00%
    Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity.
    Tecaginlimab
  • HY-P99775
    Placulumab 945781-29-3
    Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis.
    Placulumab
  • HY-P99912
    Emerfetamab 2250261-27-7
    Emerfetamab is an anti-CD3E/CD33 monoclonal antibody.
    Emerfetamab
  • HY-P99914
    Emfizatamab 2559704-23-1
    Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia.
    Emfizatamab
  • HY-P99946
    Erlizumab 211323-03-4 98.49%
    Erlizumab (rhuMAb) is a monoclonal antibody against the Integrin b2/ITGB2/CD18 subunit of the Mac-1 receptor. Erlizumab can reduce reperfusion injury in myocardial infarction.
    Erlizumab
  • HY-U00082
    Tigloidin 495-83-0 98.39%
    Tigloidin is an analogue of atropine, with anticholinergic activity.
    Tigloidin
Cat. No. Product Name / Synonyms Application Reactivity